Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 166   

Articles published

BMY 52.96 +3.67 (7.45%)
price chart
Bristol-Myers Squibb Plans Organizational Revamp, Unveils $3 Billion Share Buyback
Bristol-Myers said Wednesday that as part of its realignment, the company plans to focus more spending around its key brands and markets, make its research-and-development organization more agile, streamline certain operations and expand its abilities ...
Earnings Reaction History: Bristol Myers Squibb Co, 40.0% Follow-Through ...  Nasdaq
Bristol-Myers Squibb Alters Operating Model as Q3 Earnings Top View  ETF Daily News (blog)
Bristol-Myers Squibb Co: THIS Will Influence Where BMY Stock Goes Next
Bristol-Myers Squibb Co (NYSE:BMY) stock is still feeling the after-effects of the negative news surrounding its cancer drug “Opdivo,” which failed a study that would have expanded its use in lung cancer patients.
Can Bristol-Myers Squibb Co Turn Things Around With Q3 Earnings?  ETF Daily News (blog)
Bristol-Myers Squibb Updates Conference Call Dial-in/ID for Third Quarter ...  Business Wire (press release)
It's Big Tech Day, With Amazon, Alphabet, Twitter Stepping To The Plate
And that's not all on this huge earnings day, as we also hear from Bristol-Meyers Squibb Co (NYSE: BMY), Colgate-Palmolive Company (NYSE: CL), LinkedIn Corp (NYSE: LNKD), and United Parcel Service, Inc. (NYSE: UPS). On the Fed watch, chances for a ...
Microsoft Corporation (NASDAQ:MSFT) & Bristol-Myers Squibb Co (NYSE:BMY) Worth ...
On Tuesday, Shares of Microsoft Corporation (NASDAQ:MSFT) lost -0.02% to $60.99. The share price is trading in a range of $59.93 - 61.37.
Investor's Watch: Bristol-Myers Squibb Co (NYSE:BMY)
Bristol-Myers Squibb Co (NYSE:BMY) share price plunged -0.94% or -0.47 points to reach at $49.77 during previous trading session.
Holder Worth Mentioning: Bristol Myers Squibb Co Com (BMY) Market Value Rose ...  Chester News
Current Bristol-Myers Squibb Company (NYSE:BMY) PT Means Stock Is Worth ...  Review Fortune
Stock Update (NYSE:BMY): Bristol-Myers Squibb Co and Nektar Therapeutics ...
Bristol-Myers Squibb Co (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational medicine, NKTR-214, as a potential combination ...
Bristol-Myers to test Opdivo with Nektar drug  PharmaLive (press release) (subscription)
Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo
Stock Update (NYSE:BMY): Bristol-Myers Squibb Co Receives Positive CHMP ...
Bristol-Myers Squibb Co (NYSE:BMY) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the treatment of adult patients with relapsed or ...
Bristol Waits For The Other PD-1 Shoe To Drop  Seeking Alpha
Bristol-Myers Squibb's Coast 2 Coast 4 Cancer Ride Raises Over $1 Million for ...
Bristol-Myers Squibb's (BMY) Coast 2 Coast 4 Cancer has raised more than $1,050,000 to support Stand Up To Cancer's collaborative cancer research programs.
Volume Spiking for Shares of Bristol-Myers Squibb Company (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY activity puts the stock on today's active list. The change from open is -0.66% at the time of writing.
Bristol-Myers Shares Plunge 7% as Lung Cancer Drug Fails Again
Bristol Myers logo Drug giant Bristol-Myers Squibb Co (NYSE:BMY) saw its shares fall up to 7% in early trading today, as news broke that an important immune-based therapy once again failed a lung cancer trial.
How a Merck cancer breakthrough caused Bristol-Myers' stock to plunge  MarketWatch
Bristol plunges, Merck jumps, on contrasting lung cancer data  Business Insider